FIA
MLTX icon

FNY Investment Advisers’s MoonLake Immunotherapeutics MLTX Stock Holding History

FNY Investment Advisers’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58K Buy
+3,000
New +$54.4K 0.02% 399
2025
Q4 		– Sell
-4,000
Closed -$28K – 1236
2025
Q3 		$28K Buy
+4,000
New +$208K 0.01% 622

Other funds holding MLTX

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

FNY Investment Advisers's MLTX Position: Q2 2026 in Review

FNY Investment Advisers opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 3,000 shares worth $58K. The stake represents 0.02% of the portfolio and ranks #399 among its holdings. This is a return to the name: FNY Investment Advisers previously reported a position in MLTX as recently as Q3 2025.

FNY Investment Advisers first reported a position in MLTX in Q3 2025 and has held it in 2 quarters since. 62 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • FNY Investment Advisers held 3,000 shares of MoonLake Immunotherapeutics worth $58K as of Q2 2026.
  • MoonLake Immunotherapeutics was a new FNY Investment Advisers position in Q2 2026.
  • MoonLake Immunotherapeutics made up 0.02% of FNY Investment Advisers's portfolio in Q2 2026, its #399 holding.
  • FNY Investment Advisers first reported a position in MoonLake Immunotherapeutics in Q3 2025 and has held it in 2 quarters since.
  • 62 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.